EP4228636A4 - Zusammensetzungen und verfahren für lagerstabile ophthalmische arzneimittel - Google Patents
Zusammensetzungen und verfahren für lagerstabile ophthalmische arzneimittel Download PDFInfo
- Publication number
- EP4228636A4 EP4228636A4 EP21880707.1A EP21880707A EP4228636A4 EP 4228636 A4 EP4228636 A4 EP 4228636A4 EP 21880707 A EP21880707 A EP 21880707A EP 4228636 A4 EP4228636 A4 EP 4228636A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- storage
- stable ophthalmic
- ophthalmic medicaments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/069,155 US11273150B2 (en) | 2018-10-10 | 2020-10-13 | Compositions and methods for the treatment of presbyopia |
| PCT/US2021/029536 WO2022081204A1 (en) | 2020-10-13 | 2021-04-28 | Compositions and methods for storage stable ophthalmic drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4228636A1 EP4228636A1 (de) | 2023-08-23 |
| EP4228636A4 true EP4228636A4 (de) | 2024-11-27 |
Family
ID=81209258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21880707.1A Pending EP4228636A4 (de) | 2020-10-13 | 2021-04-28 | Zusammensetzungen und verfahren für lagerstabile ophthalmische arzneimittel |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4228636A4 (de) |
| JP (1) | JP2023544918A (de) |
| KR (1) | KR20230131822A (de) |
| CN (1) | CN116847841A (de) |
| AU (1) | AU2021361731A1 (de) |
| CA (1) | CA3195422A1 (de) |
| MX (1) | MX2023004298A (de) |
| WO (1) | WO2022081204A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210251970A1 (en) | 2018-10-10 | 2021-08-19 | Presbyopia Therapies Inc | Compositions and methods for storage stable ophthalmic drugs |
| WO2023091439A1 (en) | 2021-11-17 | 2023-05-25 | Lenz Therapeutics, Inc. | Aceclidine derivatives, compositions thereof and methods of use thereof |
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200115377A1 (en) * | 2018-10-10 | 2020-04-16 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9629852B2 (en) * | 2007-10-16 | 2017-04-25 | Sun Pharma Advanced Research Company Ltd. | Ophthalmic composition comprising a prostaglandin |
| US20190038609A1 (en) * | 2013-08-28 | 2019-02-07 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| KR20180014825A (ko) * | 2015-06-18 | 2018-02-09 | 프레스바이오피아 세라피스, 엘엘씨 | 눈의 굴절 이상 치료 및 원거리 시력 개선용 조성물 및 방법 |
-
2021
- 2021-04-28 CN CN202180081410.1A patent/CN116847841A/zh active Pending
- 2021-04-28 AU AU2021361731A patent/AU2021361731A1/en active Pending
- 2021-04-28 MX MX2023004298A patent/MX2023004298A/es unknown
- 2021-04-28 WO PCT/US2021/029536 patent/WO2022081204A1/en not_active Ceased
- 2021-04-28 CA CA3195422A patent/CA3195422A1/en active Pending
- 2021-04-28 JP JP2023547174A patent/JP2023544918A/ja active Pending
- 2021-04-28 EP EP21880707.1A patent/EP4228636A4/de active Pending
- 2021-04-28 KR KR1020237016074A patent/KR20230131822A/ko active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200115377A1 (en) * | 2018-10-10 | 2020-04-16 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023004298A (es) | 2023-08-09 |
| WO2022081204A1 (en) | 2022-04-21 |
| CN116847841A (zh) | 2023-10-03 |
| JP2023544918A (ja) | 2023-10-25 |
| EP4228636A1 (de) | 2023-08-23 |
| AU2021361731A1 (en) | 2023-05-25 |
| CA3195422A1 (en) | 2022-04-21 |
| KR20230131822A (ko) | 2023-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4228636A4 (de) | Zusammensetzungen und verfahren für lagerstabile ophthalmische arzneimittel | |
| EP3958846C0 (de) | Beschichtete wirkstoffzusammensetzungen und verfahren zur herstellung davon | |
| EP4051241A4 (de) | Pharmazeutische zusammensetzungen aus albumin und rapamycin | |
| EP3716990A4 (de) | Zusammensetzungen und verfahren für neurologische erkrankungenn | |
| EP4347859A4 (de) | Integrasezusammensetzungen und verfahren | |
| EP3877381A4 (de) | Benzamide von pyrazolyl-amino-pyrimidinyl-derivaten, zusammensetzungen und verfahren dafür | |
| EP4399306A4 (de) | Pah-modulierende zusammensetzungen und verfahren | |
| EP4308701A4 (de) | Ltr-transposon-zusammensetzungen und verfahren | |
| PL4094754T3 (pl) | Kompozycje do leczenia chorób związanych z agregacją białek i/lub zapobiegania takim chorobom | |
| EP4146151A4 (de) | Furan-tensidzusammensetzungen und verfahren | |
| EP3570670A4 (de) | Zusammensetzungen und verfahren zur behandlung lysosomalen speicherkrankheiten und -störungen | |
| EP4021844A4 (de) | Formulierung und verpackung von zusammensetzungen | |
| EP4228700A4 (de) | Verfahren und zusammensetzungen für gezielten proteinabbau | |
| EP4367198A4 (de) | Geopolymerzusammensetzungen und verfahren | |
| EP4463173A4 (de) | Postbiotische zusammensetzungen und verfahren | |
| EP3773654C0 (de) | Pharmazeutische wirkstoffzusammensetzungen und zugehörige verfahren | |
| EP3953347A4 (de) | Benzether und aniline von pyrazolyl-amino-pyrimidinylderivaten sowie zusammensetzungen und verfahren dafür | |
| EP4437108A4 (de) | Zusammensetzungen und verfahren zur behandlung neurodegenerativer erkrankungen | |
| EP3884034A4 (de) | Verfahren und zusammensetzungen zur herstellung cannabinoiden | |
| EP4084784A4 (de) | Zusammensetzungen und verfahren | |
| EP3840745A4 (de) | Verfahren und zusammensetzungen für arzneimittel zur behandlung von augenkrankheiten | |
| EP3576799A4 (de) | Ophthalmische zusammensetzungen für therapie und prophylaxe | |
| EP3600324A4 (de) | Arzneimittel und zusammensetzungen zur behandlung von augenkrankheiten | |
| EP4392037A4 (de) | Therapeutische zusammensetzungen und zugehörige verfahren | |
| EP4504952A4 (de) | Zusammensetzungen und verfahren für muskelerkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230510 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LENZ THERAPEUTICS OPERATIONS, INC. |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20241030 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/10 20170101ALI20241024BHEP Ipc: A61K 31/4409 20060101ALI20241024BHEP Ipc: A61K 31/439 20060101AFI20241024BHEP |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Free format text: CASE NUMBER: APP_4680/2025 Effective date: 20250128 |
|
| RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LENZ THERAPEUTICS OPERATIONS, INC. |